Hodgkın Lenfoma Tanılı Hastada Brentuksımab Vedotın İlişkili Cytomegalovırus Retiniti
Özet
Antimikrotübül ajan monometil auristatin E'ye bağlı anti-CD30 antikorundan oluşan bir antikor-ilaç konjugatı olan Brentuksimab Vedotin, Hodgkin lenfoma ve Sistemik Anaplastik Büyük Hücreli Lenfoma hastalarının tedavisinde kullanılmaktadır. Bildirilen en yaygın yan etkiler periferik duysal nöropati, bulantı, alopesi ve sitopeni iken az sayıda Brentuksimab Vedotin kaynaklı sitomegalovirüs reaktivasyonu vakası bildirilmiştir. Literatür bilgimize göre, Hodgkin Lenfoma tanılı hasta popülasyonunda sitomegalovirüs reaktivasyonu ve hastalığı nadirdir. Vakamız, otolog kök hücre nakli sonrası nüks gelişen Hodgkin lenfoma tanılı 29 yaşında bir erkek hastada Brentuksimab Vedotin tedavisi sonrasında gelişen sitomegalovirüs reaktivasyonu ve buna bağlı hastalığın nadir bir şekli olan sitomegalovirüs retiniti ile ilgilidir.
Referanslar
Schmitz, N., et al., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 2002. 359(9323): p. 2065-71.
Tarella, C., et al., High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer, 2003. 97(11): p. 2748-59.
Hsu, F.Y., et al., The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Cancer Res, 2006. 66(18): p. 9002-8.
Savage, K.J., et al., ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood, 2008. 111(12): p. 5496-504.
Tudesq, J.J., et al., Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30(+) Lymphoma. Open Forum Infect Dis, 2017. 4(2): p. ofx091.
Tambe, A., et al., Cytomegalovirus Pneumonia Causing Acute Respiratory Distress Syndrome After Brentuximab Vedotin Therapy. Am J Ther, 2019. 26(6): p. e794-e795.
Goldman, J.D., et al., COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer, 2021. 9(6).
Jakobsen, N.A. and P. Vyas, From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia. Clin Med (Lond), 2018. 18(Suppl 2): p. s47-s53.
Aizawa, S., et al., Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem, 1997. 272(4): p. 2042-5.
Katz, J., J.E. Janik, and A. Younes, Brentuximab Vedotin (SGN-35). Clin Cancer Res, 2011. 17(20): p. 6428-36.
Younes, A., et al., Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med, 2010. 363(19): p. 1812-21.
Younes, A., et al., Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol, 2012. 30(18): p. 2183-9.
Pro, B., et al., Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol, 2012. 30(18): p. 2190-6.
Ferreri, A.J., et al., Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol, 2012. 83(2): p. 293-302.
Teicher, B.A. and R.V. Chari, Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res, 2011. 17(20): p. 6389-97.
Raulet, D.H., Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol, 2004. 5(10): p. 996-1002.
Bowen, M.A., et al., Structure and expression of murine CD30 and its role in cytokine production. J Immunol, 1996. 156(2): p. 442-9.
Fu, Y.X., et al., Lymphotoxin-alpha-dependent spleen microenvironment supports the generation of memory B cells and is required for their subsequent antigen-induced activation. J Immunol, 2000. 164(5): p. 2508-14.
Boeckh, M., Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program, 2011. 2011: p. 305-9.
Pertel, P., et al., Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr (1988), 1992. 5(11): p. 1069-74.
Crippa, F., et al., Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis, 2001. 32(2): p. 214-9.
Andreescu, M., Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies. Life (Basel), 2023. 13(6).
Gopal, A.K., et al., Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood, 2012. 120(3): p. 560-8.
Bekiaris, V., et al., NK cells protect secondary lymphoid tissue from cytomegalovirus via a CD30-dependent mechanism. Eur J Immunol, 2009. 39(10): p. 2800-8.
Referanslar
Schmitz, N., et al., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 2002. 359(9323): p. 2065-71.
Tarella, C., et al., High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer, 2003. 97(11): p. 2748-59.
Hsu, F.Y., et al., The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Cancer Res, 2006. 66(18): p. 9002-8.
Savage, K.J., et al., ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood, 2008. 111(12): p. 5496-504.
Tudesq, J.J., et al., Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30(+) Lymphoma. Open Forum Infect Dis, 2017. 4(2): p. ofx091.
Tambe, A., et al., Cytomegalovirus Pneumonia Causing Acute Respiratory Distress Syndrome After Brentuximab Vedotin Therapy. Am J Ther, 2019. 26(6): p. e794-e795.
Goldman, J.D., et al., COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer, 2021. 9(6).
Jakobsen, N.A. and P. Vyas, From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia. Clin Med (Lond), 2018. 18(Suppl 2): p. s47-s53.
Aizawa, S., et al., Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem, 1997. 272(4): p. 2042-5.
Katz, J., J.E. Janik, and A. Younes, Brentuximab Vedotin (SGN-35). Clin Cancer Res, 2011. 17(20): p. 6428-36.
Younes, A., et al., Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med, 2010. 363(19): p. 1812-21.
Younes, A., et al., Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol, 2012. 30(18): p. 2183-9.
Pro, B., et al., Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol, 2012. 30(18): p. 2190-6.
Ferreri, A.J., et al., Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol, 2012. 83(2): p. 293-302.
Teicher, B.A. and R.V. Chari, Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res, 2011. 17(20): p. 6389-97.
Raulet, D.H., Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol, 2004. 5(10): p. 996-1002.
Bowen, M.A., et al., Structure and expression of murine CD30 and its role in cytokine production. J Immunol, 1996. 156(2): p. 442-9.
Fu, Y.X., et al., Lymphotoxin-alpha-dependent spleen microenvironment supports the generation of memory B cells and is required for their subsequent antigen-induced activation. J Immunol, 2000. 164(5): p. 2508-14.
Boeckh, M., Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program, 2011. 2011: p. 305-9.
Pertel, P., et al., Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr (1988), 1992. 5(11): p. 1069-74.
Crippa, F., et al., Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis, 2001. 32(2): p. 214-9.
Andreescu, M., Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies. Life (Basel), 2023. 13(6).
Gopal, A.K., et al., Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood, 2012. 120(3): p. 560-8.
Bekiaris, V., et al., NK cells protect secondary lymphoid tissue from cytomegalovirus via a CD30-dependent mechanism. Eur J Immunol, 2009. 39(10): p. 2800-8.
